Interferon-α is able to maintain complete molecular remission induced by imatinib after its discontinuation

[1]  Brian C. Smith,et al.  Acetyl-lysine Analog Peptides as Mechanistic Probes of Protein Deacetylases* , 2007, Journal of Biological Chemistry.

[2]  M. Deininger,et al.  Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. , 2007, Blood.

[3]  P. Marks,et al.  Histone deacetylase inhibitors: molecular mechanisms of action , 2007, Oncogene.

[4]  G. Cohen,et al.  Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa , 2007, Leukemia.

[5]  Eric Verdin,et al.  Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[6]  K. Garber.  HDAC inhibitors overcome first hurdle , 2007, Nature Biotechnology.

[7]  C. Elferink,et al.  Requirement of biphasic calcium release from the endoplasmic reticulum for Fas-mediated apoptosis , 2006, The Journal of cell biology.

[8]  F. J. Caballero,et al.  Basiliolides, a Class of Tetracyclic C19 Dilactones from Thapsia garganica, Release Ca2+ from the Endoplasmic Reticulum and Regulate the Activity of the Transcription Factors Nuclear Factor of Activated T Cells, Nuclear Factor-κB, and Activator Protein 1 in T Lymphocytes , 2006, Journal of Pharmacology and Experimental Therapeutics.

[9]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[10]  N. Grishin,et al.  Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. , 2006, Molecular cell.

[11]  E. Seto,et al.  Histone Deacetylase 8 Safeguards the Human Ever-Shorter Telomeres 1B (hEST1B) Protein from Ubiquitin-Mediated Degradation , 2006, Molecular and Cellular Biology.

[12]  S. Kanba,et al.  Depletion of intracellular Ca2+ store itself may be a major factor in thapsigargin-induced ER stress and apoptosis in PC12 cells , 2006, Neurochemistry International.

[13]  Z. Cao,et al.  CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo , 2006, Molecular Cancer Therapeutics.

[14]  L. Samelson,et al.  Recruitment and activation of PLCγ1 in T cells: a new insight into old domains , 2006 .

[15]  E. Seto,et al.  Acetylation and deacetylation of non-histone proteins. , 2005, Gene.

[16]  S. Snyder,et al.  Phospholipase C-γ: diverse roles in receptor-mediated calcium signaling , 2005 .

[17]  O. Wiest,et al.  Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. , 2005, Journal of medicinal chemistry.

[18]  S. Schreiber,et al.  Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Eric Verdin,et al.  Histone deacetylase HDAC8 associates with smooth muscle α‐actin and is essential for smooth muscle cell contractility , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  P. Marks,et al.  Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid , 2005, Nature Clinical Practice Oncology.

[21]  Asif J. Chaudhry,et al.  Ras-Raf-Arf Signaling Critically Depends on the Dmp1 Transcription Factor , 2005, Molecular and Cellular Biology.

[22]  R. De Francesco,et al.  Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  B. Schultz,et al.  Kinetics and comparative reactivity of human class I and class IIb histone deacetylases. , 2004, Biochemistry.

[24]  A. Doweyko,et al.  Selective Itk inhibitors block T-cell activation and murine lung inflammation. , 2004, Biochemistry.

[25]  J. R. Somoza,et al.  Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. , 2004, Structure.

[26]  R. Rizzuto,et al.  Participation of endoplasmic reticulum and mitochondrial calcium handling in apoptosis: more than just neighborhood? , 2004, FEBS letters.

[27]  K. Moutairou,et al.  Modulation of intracellular calcium concentrations and T cell activation by prickly pear polyphenols , 2004, Molecular and Cellular Biochemistry.

[28]  Ivan V. Gregoretti,et al.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. , 2004, Journal of molecular biology.

[29]  S. Grant,et al.  Histone deacetylase inhibitors in clinical development , 2004, Expert opinion on investigational drugs.

[30]  E. Seto,et al.  Negative Regulation of Histone Deacetylase 8 Activity by Cyclic AMP-Dependent Protein Kinase A , 2004, Molecular and Cellular Biology.

[31]  S. Snyder,et al.  Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis , 2003, Nature Cell Biology.

[32]  Ricardo Macarron,et al.  Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases , 2003, Journal of Pharmacology and Experimental Therapeutics.

[33]  F. Dequiedt,et al.  Class II histone deacetylases: versatile regulators. , 2003, Trends in genetics : TIG.

[34]  Stuart L Schreiber,et al.  Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[36]  C. Creaser,et al.  Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. , 2001, Blood.

[37]  S. Watson,et al.  Regulation of phospholipase C γ isoforms in haematopoietic cells , 2001 .

[38]  D. Bernhard,et al.  The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R. Abraham,et al.  Pleiotropic Contributions of Phospholipase C-γ1 (PLC-γ1) to T-Cell Antigen Receptor-Mediated Signaling: Reconstitution Studies of a PLC-γ1-Deficient Jurkat T-Cell Line , 2000, Molecular and Cellular Biology.

[40]  Mark M. Davis,et al.  Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia , 2000, Nature Medicine.

[41]  J. Clark,et al.  Cloning and characterization of a novel human histone deacetylase, HDAC8. , 2000, The Biochemical journal.

[42]  J. Cleveland,et al.  Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors. , 2000, Immunity.

[43]  R. Abraham,et al.  Functional analysis of LAT in TCR-mediated signaling pathways using a LAT-deficient Jurkat cell line. , 1999, International immunology.

[44]  F. Benvenuto,et al.  Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. , 1999, Blood.

[45]  M. Katan.  Families of phosphoinositide-specific phospholipase C: structure and function. , 1998, Biochimica et biophysica acta.

[46]  A. Ribas,et al.  Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. , 1998, Journal of immunology.

[47]  S. Bunnell,et al.  T Cell Receptor–initiated Calcium Release Is Uncoupled from Capacitative Calcium Entry in Itk-deficient T Cells , 1998, The Journal of experimental medicine.

[48]  S. Christensen,et al.  A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca(2+)-ATPases. , 1998, Trends in pharmacological sciences.

[49]  C. Reutelingsperger,et al.  Early Features of Apoptosis Detected by Four Different Flow Cytometry Assays , 1998, Apoptosis.

[50]  U. Gullberg,et al.  Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program , 1998, Oncogene.

[51]  A. Sette,et al.  Specific human cellular immunity to bcr-abl oncogene-derived peptides. , 1996, Blood.

[52]  T. Curran,et al.  Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. , 1990, Science.

[53]  R. Smith,et al.  Receptor-coupled signal transduction in human polymorphonuclear neutrophils: effects of a novel inhibitor of phospholipase C-dependent processes on cell responsiveness. , 1990, The Journal of pharmacology and experimental therapeutics.

[54]  T. Mak,et al.  Reconstitution of an active surface T3/T-cell antigen receptor by DNA transfer , 1985, Nature.

[55]  Weiping Zheng,et al.  A spectrophotometric assay for histone deacetylase 8. , 2008, Analytical biochemistry.

[56]  Ronald Breslow,et al.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.

[57]  A. El-Osta,et al.  Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? , 2007, Leukemia.

[58]  D. Bikle,et al.  Phospholipase cgamma1 is required for activation of store-operated channels in human keratinocytes. , 2005, The Journal of investigative dermatology.

[59]  Martin C. Müller,et al.  Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. , 2003, Blood.